Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

PURPOSE: To define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02, a novel liposome-encapsulated irinotecan, in patients with advanced refractory solid tumors. METHODS: Patients were enrolled in cohorts of one to three to receive escalating dose of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, T. C., Shiah, H. S., Yang, C. H., Yeh, K. H., Cheng, A. L., Shen, B. N., Wang, Y. W., Yeh, C. G., Chiang, N. J., Chang, J. Y., Chen, L. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341010/
https://www.ncbi.nlm.nih.gov/pubmed/25577133
http://dx.doi.org/10.1007/s00280-014-2671-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341010/
https://www.ncbi.nlm.nih.gov/pubmed/25577133
http://dx.doi.org/10.1007/s00280-014-2671-x

Ejemplares similares